Emerging peptide · Mid-stage emerging

Ribupatide (HRS9531)

Hengrui Pharma's weekly dual GIP/GLP-1 agonist, now carrying the INN ribupatide. It has been filed for approval in China, and Kailera's global Phase 3 program finished enrolling in September 2026.

Phase 3 (filed in China)

Investigational compounds, read carefully

This section covers peptides at the frontier of research. Most entries are preclinical, in early or mid-stage clinical trials, or theoretical. Evidence levels are explicitly marked on every entry.

Nothing on these pages constitutes medical advice, dosing recommendations, or instructions for use. Many of these compounds are not commercially available; some are not legal for human use. Decisions about treatment require a qualified clinician.

At a glance

A Chinese-developed dual incretin agonist whose 48-week Phase 3 trial in China reported up to 17.7% weight loss. Hengrui has filed it with China's regulator, and the global KaiNETIC Phase 3 program is fully enrolled, with results expected in mid-2028.

Class
Dual GIP/GLP-1 receptor agonist
Sponsor
Jiangsu Hengrui Pharmaceuticals (China); Kailera Therapeutics (rest of world)
Stage
Approval filing in China; global Phase 3 fully enrolled
Lead use case
Obesity and type 2 diabetes

What it is

Ribupatide (development code HRS9531, and KAI-9531 outside China) is a synthetic peptide dual agonist of the GIP and GLP-1 receptors developed by Jiangsu Hengrui Pharmaceuticals. In May 2024 Hengrui licensed rights outside Greater China to Kailera Therapeutics. It is part of the broader emergence of Chinese metabolic-disease pharmacology programs that have produced mazdutide, ecnoglutide, and several other incretin candidates.

Current research status

Hengrui has studied the weekly injection in more than 3,000 participants in late-stage trials in China and has submitted an approval application to China's National Medical Products Administration for long-term weight management. No Chinese approval had been announced as of mid-October 2026.[3]

Outside China, Kailera completed enrollment in the KaiNETIC Phase 3 program on September 30, 2026: about 4,900 adults across three 76-week trials, one of which (KaiNETIC-3) compares ribupatide with semaglutide 2.4 mg. Topline results are expected in mid-2028. An oral form is also moving into Phase 3 in China.[3]

Mechanistic rationale

Standard dual GIP/GLP-1 receptor agonism, the same mechanism as tirzepatide. The GLP-1 arm contributes appetite suppression, slowed gastric emptying, and glucose-dependent insulin release; the GIP arm contributes additional adipose-tissue and central appetite effects. The molecular tuning of the two receptor affinities is the differentiation among compounds in this class.

Available evidence

HRS9531-301 (Phase 3, China, topline July 2025), 567 adults with obesity or overweight plus a comorbidity, without diabetes, randomised to 2, 4 or 6 mg weekly or placebo for 48 weeks. Weight loss reached up to 17.7% (16.3% placebo-adjusted) in the primary analysis, and up to 19.2% if everyone had stayed on treatment. Most side effects were mild to moderate and gastrointestinal. Per-dose figures and discontinuation rates were not disclosed in the topline release.[1]

Why it's interesting

The Chinese metabolic-disease pharmacology landscape has matured considerably and is increasingly producing molecules competitive with the lead Western programs. Ribupatide, mazdutide, and ecnoglutide collectively suggest the next decade of obesity therapeutics will be more globally distributed than the past decade has been. From a pure-pharmacology standpoint, ribupatide's results in the same range as tirzepatide indicate the GIP/GLP-1 dual-agonist class is reproducible across molecular variants.

Limitations & risks

Western regulatory pathways for ribupatide are behind the Chinese pathway: the global trials will not read out until 2028. Differences in trial-design conventions, regulatory standards, and post-approval surveillance between China and Western jurisdictions are part of how the molecule will be evaluated as it pursues broader markets. No head-to-head data against tirzepatide exists, and the semaglutide comparison in KaiNETIC-3 is open-label.

Community discussion notes

Part of a broader pattern in 2024-2025 of Chinese metabolic compounds entering Reddit and biohacker discussion as alternatives to Western brand-name products, often via grey-market sourcing. The compound itself is investigational; what's sold under these names in research-peptide channels has not been independently verified.

The takeaway

Ribupatide represents the increasing globalization of obesity-therapeutic development. The molecule has Phase 3 data in China and a fully enrolled global program; the broader signal, that competitive incretin programs are now developing across multiple regions, is likely to shape access and pricing dynamics for the next decade.

References

  1. Hengrui Pharma and Kailera Therapeutics. Positive topline data from Phase 3 obesity trial in China of dual GLP-1/GIP receptor agonist HRS9531 (HRS9531-301, NCT06396429). July 2025. https://www.biospace.com/press-releases/hengrui-pharma-and-kailera-therapeutics-report-positive-topline-data-from-phase-3-obesity-trial-in-china-of-dual-glp-1-gip-receptor-agonist-hrs9531
  2. Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes. Diabetes Ther. 2021;12(1):143-157. https://pubmed.ncbi.nlm.nih.gov/33325008/
  3. Kailera Therapeutics. Completion of enrollment in KaiNETIC global Phase 3 clinical program of GLP-1/GIP receptor dual agonist ribupatide injection. September 30, 2026. https://finviz.com/news/396900/kailera-therapeutics-announces-completion-of-enrollment-in-kainetic-global-phase-3-clinical-program-of-glp-1gip-receptor-dual-agonist-ribupatide-injection